Sobi gets EU nod for Doptelet in rare blood disorder ITPSweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the Share XSobi gets EU nod for Doptelet in rare blood disorder ITPhttps://pharmaphorum.com/news/sobi-gets-eu-nod-for-doptelet-in-rare-blood-disorder-itp/
FDA to expedite development of two Sanofi rare disease drugsThe FDA has agreed to expedite development of two rare disease drugs from Sanofi. The most significant of Share XFDA to expedite development of two Sanofi rare disease drugshttps://pharmaphorum.com/news/fda-to-expedite-development-of-two-sanofi-rare-disease/
